fraxiparine forte 19000 i.e. anti-xa/1,0 ml raztopina za injiciranje
aspen pharma trading limited - kalcijev nadroparinat - raztopina za injiciranje - kalcijev nadroparinat 19000 i.e. / 1 ml - nadroparin
fraxiparine forte 15200 i.e. anti-xa/0,8 ml raztopina za injiciranje
aspen pharma trading limited - kalcijev nadroparinat - raztopina za injiciranje - kalcijev nadroparinat 15200 i.e. / 0,8 ml - nadroparin
clopidogrel viatris (previously clopidogrel taw pharma)
viatris limited - klopidogrel besilat - peripheral vascular diseases; stroke; myocardial infarction - antitrombotična sredstva - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st segmentu višinskih akutni miokardni infarkt, v kombinaciji s asa v medicinsko zdravljenih bolnikih, ki izpolnjujejo pogoje za thrombolytic terapija. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. za nadaljnje informacije, prosimo, preberite razdelek 5.
clopidogrel taw pharma (previously clopidogrel mylan)
taw pharma (ireland) limited - klopidogrel hidroklorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotična sredstva - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:, - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). , - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.
azacitidine mylan
mylan ireland limited - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastična sredstva - azacitidine mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29% marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30% blasts and multi lineage dysplasia, according to world health organisation (who) classification,aml with > 30% marrow blasts according to the who classification.
donepezil mylan 10 mg orodisperzibilne tablete
mylan ireland limited - donepezil - orodisperzibilna tableta - donepezil 9,12 mg / 1 tableta - donepezil
donepezil mylan 5 mg orodisperzibilne tablete
mylan ireland limited - donepezil - orodisperzibilna tableta - donepezil 4,56 mg / 1 tableta - donepezil
ivabradin mylan 5 mg filmsko obložene tablete
mylan ireland limited - ivabradin - filmsko obložena tableta - ivabradin 5 mg / 1 tableta - ivabradin
ivabradin mylan 7,5 mg filmsko obložene tablete
mylan ireland limited - ivabradin - filmsko obložena tableta - ivabradin 7,5 mg / 1 tableta - ivabradin
dovprela (previously pretomanid fgk)
mylan ire healthcare limited - pretomanid - tuberkuloza, odporna proti multidrugom - antimikobakterij - dovprela is indicated in combination with bedaquiline and linezolid, in adults, for the treatment of pulmonary extensively drug resistant (xdr), or treatment-intolerant or nonresponsive multidrug-resistant (mdr) tuberculosis (tb). upoštevati je treba uradne smernice za ustrezno uporabo protibakterijsko agenti.